Vor Biopharma (NASDAQ:VOR) Downgraded by Wall Street Zen to Strong Sell

Vor Biopharma (NASDAQ:VOR) was downgraded by equities researchers at Wall Street Zen to a “strong sell” rating in a note issued to investors on Saturday.

Vor Biopharma Price Performance

Vor Biopharma stock opened at $1.06 on Friday. The company has a market capitalization of $132.46 million, a P/E ratio of -0.70 and a beta of -0.51.

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.